title: Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group.
abstract: BACKGROUND
  In the present phase II multicenter study, we assessed the efficacy and tolerability of the combination of gemcitabine and carboplatin in patients with advanced pancreatic cancer.
  
  
  METHODS
  Patients with previously untreated, locally advanced or metastatic pancreatic cancer were treated with gemcitabine 800 mg/m(2) on days 1 and 8 and carboplatin at an AUC of 4 on day 8 of a 3-week cycle, for a total of six cycles. Primary end points were response rate and clinical benefit; secondary end points were, survival, time to progression (TTP) and toxicity.
  
  
  RESULTS
  A total of 50 patients were enrolled in the study, 47 of whom were eligible for treatment. The median age was 63 years (range 34-76) and the median Karnofsky performance status (PS) was 80%. Patients received a median of six cycles (range 1-11). Among 35 patients evaluable for response, eight (17%) achieved partial response; 15 (32%) and 12 (25%) patients had stable and progressive disease, respectively. The median overall survival was 7.4 months; the median TTP was 4.4 months and the 1-year survival was 28%. The observed clinical benefit response was remarkable. After the second cycle of chemotherapy, 21 of 31 (68%) patients experienced pain improvement and reduced analgesic consumption. At the same time, 35% and 56% of our patients significantly improved their Karnofsky PS and weight, respectively. Overall, the treatment was well tolerated. The most common grade 3-4 toxicities were hematological, including 8% anemia, 6% neutropenia and 13% thrombocytopenia.
  
  
  CONCLUSIONS
  The combination of gemcitabine plus carboplatin is a moderately active treatment for patients with locally advanced and metastatic pancreatic cancer. This regimen has an acceptable toxicity profile and provides a significant clinical benefit, and hence warrants further investigation.
authors.affiliation: Second Department of Internal Medicine, Propaedeutic and Research Institute, University General Hospital 'Attikon', University of Athens, Greece. nxiros@otenet.gr
authors.forename: N
authors.initials: N
authors.lastname: Xiros
authors.forename: P
authors.initials: P
authors.lastname: Papacostas
authors.forename: T
authors.initials: T
authors.lastname: Economopoulos
authors.forename: G
authors.initials: G
authors.lastname: Samelis
authors.forename: E
authors.initials: E
authors.lastname: Efstathiou
authors.forename: E
authors.initials: E
authors.lastname: Kastritis
authors.forename: H
authors.initials: H
authors.lastname: Kalofonos
authors.forename: A
authors.initials: A
authors.lastname: Onyenadum
authors.forename: D
authors.initials: D
authors.lastname: Skarlos
authors.forename: A
authors.initials: A
authors.lastname: Bamias
authors.forename: H
authors.initials: H
authors.lastname: Gogas
authors.forename: D
authors.initials: D
authors.lastname: Bafaloukos
authors.forename: E
authors.initials: E
authors.lastname: Samantas
authors.forename: P
authors.initials: P
authors.lastname: Kosmidis
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000009:adverse effects / Q000627:therapeutic use; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D006115:Greece; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010166:Palliative Care; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D011379:Prognosis; D011788:Quality of Life; D018570:Risk Assessment; D016019:Survival Analysis; D019452:Terminally Ill; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D016190:Carboplatin; D000093542:Gemcitabine